Pipeline

Our Pipeline is comprised of Biologics, including the proprietary BEAT® MultispecificsTM platform, and one Cbl-b inhibitor small molecule targeting the spectrum of hematological cancers and solid tumors. If you are interested in exploring a partnership, Contact us.

Oncology

Diversity of Immune Cell Engagement and Indications across Hematologic and Solid Tumors

ASSETS DESCRIPTION INDICATION
CLINICAL ASSETS
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
STATUS

BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager

Multiple Myeloma

PHASE 1
ORPHAN DRUG

GRC 65327

Cbl-b Inhibitor Small Molecule

Solid Tumors

PRE-CLINICAL

CANDIDATES

ISB 2301

IMMUNITE™ NK-Cell Engager

Solid Tumors

DISCOVERY

PRODUCTS

COMPOUND

CLINICAL ASSETS

TARGET
BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager

INDICATION
Multiple Myeloma

PHASE

STATUS : 
PHASE 1 ORPHAN DRUG

PRODUCTS

COMPOUND
CLINICAL ASSETS
GRC 65327

TARGET
Cbl-b Inhibitor Small Molecule

INDICATION
Solid Tumors

PHASE

STATUS :
PRE-CLINICAL

PRODUCTS

COMPOUND
CANDIDATES
ISB 2301

TARGET
IMMUNITE™
NK-Cell Engager

INDICATION
Solid Tumors

PHASE

STATUS :
DISCOVERY

ISB 2001 is first TREATTM Trispecific Antibody for
Relapsed/Refractory Multiple Myeloma

KEY ATTRIBUTES
  • BCMA and CD38 are expressed on the surface of multiple myeloma cells 
and are clinically validated targets.

  • ISB 2001 combines three proprietary Fab arms binding to CD3 on T-cells, and to BCMA and CD38 on myeloma cells.

  • In vitro studies showed increased killing potency of tumor cells compared to all tested antibodies, including currently approved and investigational multiple myeloma therapies.

  • In vivo studies in multiple myeloma models also show superior potency relative to antibodies for the treatment of multiple myeloma.

  • ISB 2001 redirects CD3+ T lymphocytes to kill tumor cells expressing from low 

    to high levels of both BCMA and CD38.

  • With two different tumor-associated antigens, ISB 2001 is expected to be more resistant to antigen escape associated with treatment of MM patients
    .
  • ISB 2001 was granted ODD by the U.S. FDA
isb2001_new
TREAT™: Trispecific Engagement by Antibodies based on the TCR MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity

AML: Acute Myeloid Leukemia
For collaborations, please contact us here.

Inflammation and Autoimmune Disease

The autoimmune disease assets have been out-licensed to enable greater focus on oncology. Explore the pipeline chart below to learn more and Contact Us  for additional information.

Autoimmune Disease

PRODUCTS
Telazorlimab (and ISB 830-X8)

DESCRIPTION
OX40 antagonist
Monoclonal Antibody

Atopic Dermatitis*​

Alliance Partner

astria

$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales

STATUS
SUCCESSFUL
PHASE 2B*

PRODUCTS
ISB 830-X8/STR-310

DESCRIPTION
OX40 antagonist
Monoclonal Antibody

Atopic Dermatitis*​

Alliance Partner

astria

$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales

STATUS
PRE-CLINICAL

Asset/ MOA
ISB 880 / ALM27134

STATUS
IL-1RAP antagonist
Monoclonal Antibody

Hidradenitis Suppurativa

Alliance Partner

almirali

€20.8 million for upfront payment. Plus development, regulatory and sales milestone payments,
and tiered royalties on global sales

PRODUCTS DESCRIPTION
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
STATUS

Licensed to

$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales

Telazorlimab

ISB 830-X8/STR-310

Atopic Dermatitis*​


SUCCESSFUL
PHASE 2B*

ISB 830-X8/STR-310

OX40 antagonist
Monoclonal Antibody

PRE-CLINICAL

Licensed to

€20.8 million for upfront payment. Plus development, regulatory and sales milestone payments,
and tiered royalties on global sales

ISB 880/ALM27134

IL-1RAP antagonist
Monoclonal Antibody

Hidradenitis Suppurativa

PHASE 1

*A US IND for rheumatoid arthritis and other autoimmune indications is active.

Partnering-Ready Assets to Accelerate Short-Term Value Creation

PRODUCTS

ASSETS
CLINICAL ASSETS
ISB 1342

DESCRIPTION
CD38 x CD3 BEAT® bispecific T-Cell Engager

INDICATION
Multiple Myeloma

PHASE

STATUS : 
PHASE 1 ORPHAN DRUG

PRODUCTS

ASSETS
CLINICAL ASSETS
ISB 1442

DESCRIPTION
CD38 biparatopic x CD47 BEAT® Myeloid-Cell Engager

INDICATION
Multiple Myeloma; AML planned

PHASE

STATUS : 
PHASE 1 ORPHAN DRUG

ASSETS DESCRIPTION INDICATION
CLINICAL ASSETS
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
STATUS
ISB 1342
CD38 x CD3 BEAT® bispecific T-Cell Engager
Multiple Myeloma

PHASE 1
ORPHAN DRUG

ISB 1442
CD38 biparatopic x CD47 BEAT® Myeloid-Cell Engager
Multiple Myeloma; AML planned

PHASE 1
ORPHAN DRUG